Craig-Hallum Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $36

Benzinga Newsdesk www.benzinga.com Neutral 54.0%

Neg 0% Neu 54% Pos 0%

Craig-Hallum analyst Adam Vogel initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $36.